Dr. Sepp-Lorenzino is currently a Scientific Advisor at Intellia, where she is focused on harnessing CRISPR-based gene editing technologies for human therapeutic use. She previously served as the company’s Chief Scientific Officer, overseeing all platform, pipeline research and early development activities across in vivo and ex vivo (engineered cell therapy) areas. Her career spans more than three decades in the biopharmaceutical industry and academia. Before joining Intellia, she served in senior leadership roles at Vertex Pharmaceuticals, Alnylam Pharmaceuticals and Merck & Co., guiding research on nucleic acid therapies across multiple therapeutic areas and delivering new innovations to the clinic. Dr. Sepp-Lorenzino received her professional degree in Biochemistry from the University of Buenos Aires, Argentina and both her MS and PhD in Biochemistry from New York University.